Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, presented new clinical performance data on its Foresight CLARITY™ circulating tumor DNA (ctDNA) assay at the IASLC 2025 World Conference on Lung Cancer in Barcelona. The presentation, conducted in partnership with University Health Network’s Princess Margaret Cancer Centre, highlighted MRD detection in stage I non-small cell lung cancer (NSCLC) patients enrolled in the ctDNA-Lung DETECT study.
Science Significance
Foresight CLARITY™ demonstrated high sensitivity for MRD detection, identifying ctDNA in 68% of patients pre-operatively and 38% post-operatively. Importantly, post-surgical MRD positivity correlated with worse recurrence-free survival (RFS), with hazard ratios of 3.14 at the post-operative landmark and 8.20 at the one-year follow-up. These findings indicate that ultrasensitive ctDNA assays can detect molecular residual disease earlier than conventional methods, providing a potential tool to guide adjuvant therapy decisions in early-stage NSCLC.
Regulatory Significance
The assay is currently for research use only, but the clinical data support its potential as a biomarker for precision oncology trials and regulatory submissions. High-sensitivity MRD detection could inform patient stratification and accelerate the evaluation of targeted therapies in early-stage lung cancer, helping regulatory bodies assess treatment efficacy more accurately.
Business Significance
Advertisement
The Foresight CLARITY™ platform strengthens the company’s position in the growing liquid biopsy market, which is increasingly focused on early detection and treatment monitoring. By generating robust clinical evidence for its assay in stage I NSCLC, Foresight Diagnostics demonstrates its capability to support pharmaceutical partnerships, clinical trial collaborations, and future commercialization strategies.
Patients’ Significance
For patients with early-stage lung cancer, the ability to detect MRD before or after surgery could allow for more personalized interventions, potentially reducing relapse risk and improving long-term outcomes. The study’s findings suggest that high-risk patients may be identified earlier, allowing clinicians to escalate therapy in a timely manner and provide more targeted care.
Policy Significance
The research underscores the importance of supporting high-sensitivity diagnostic assays within precision oncology frameworks. Advances in MRD detection can inform evidence-based guidelines and policies for post-surgical management of NSCLC, shaping how clinical care pathways are designed for patients with minimal residual disease.
Transaction Highlights
The study analyzed ctDNA from stage I NSCLC patients in the ctDNA-Lung DETECT trial, demonstrating high pre- and post-operative detection rates. The correlation between MRD positivity and clinical outcomes strengthens the assay’s validity as a surrogate biomarker. The IASLC 2025 oral presentation was delivered by Dr. Natasha Leighl of UHN’s Princess Margaret Cancer Centre, highlighting actionable insights for physicians and biopharmaceutical stakeholders.
Source: Foresight Diagnostics, Inc. Press Release
